Regent Pacific Group Ltd
00575
Company Profile
Business description
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Contact
5 Queen's Road Central
8th Floor, Henley Building
Hong Kong
HKGT: +852 25146111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
Record production for Woodside
Our fair value is updated as progress is made on new development projects.
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 94.40 | -1.02% |
| CAC 40 | 8,126.53 | 55.17 | 0.68% |
| DAX 40 | 24,538.81 | 229.35 | 0.94% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,223.54 | 51.78 | 0.51% |
| HKSE | 27,387.11 | 580.98 | -2.08% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 53,322.85 | 52.75 | -0.10% |
| NZX 50 Index | 13,360.10 | 63.08 | -0.47% |
| S&P 500 | 6,939.03 | 29.98 | -0.43% |
| S&P/ASX 200 | 8,869.10 | 86.00 | -0.96% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |